个人中心 - 老虎社区

crisscut

IP属地：未知

帖子 · 41帖子 · 41
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- crisscutcrisscut
  ·2021-11-06
  Hi pls like
  非常抱歉，此主贴已删除
  1,929 2
  7
  分享
  举报
- crisscutcrisscut
  ·2021-11-05
  Like pls
  S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares
  - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1
  S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares
  713 1
  4
  分享
  举报
- crisscutcrisscut
  ·2021-11-04
  Like
  非常抱歉，此主贴已删除
  940 4
  9
  分享
  举报
- crisscutcrisscut
  ·2021-11-03
  Like
  非常抱歉，此主贴已删除
  887 1
  4
  分享
  举报
- crisscutcrisscut
  ·2021-10-17
  Like pls
  非常抱歉，此主贴已删除
  1,366 2
  9
  分享
  举报
- crisscutcrisscut
  ·2021-10-15
  like
  非常抱歉，此主贴已删除
  996 评论
  2
  分享
  举报
- crisscutcrisscut
  ·2021-10-15
  like
  非常抱歉，此主贴已删除
  1,059 评论
  点赞
  分享
  举报
- crisscutcrisscut
  ·2021-10-15
  like
  非常抱歉，此主贴已删除
  751 评论
  点赞
  分享
  举报
- crisscutcrisscut
  ·2021-09-30
  like
  非常抱歉，此主贴已删除
  1,605 1
  9
  分享
  举报
- crisscutcrisscut
  ·2021-09-24
  Like
  IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.
  (Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price. Company & Technology S
  IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.
  963 评论
  6
  分享
  举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2025 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582695539757022","uuid":"3582695539757022","gmtCreate":1619601515676,"gmtModify":1620872802628,"name":"crisscut","pinyin":"crisscut","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":495,"tweetSize":41,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":842250689,"gmtCreate":1636185778518,"gmtModify":1636185778803,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"Hi pls like","listText":"Hi pls like","text":"Hi pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/842250689","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":1929,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846230147,"gmtCreate":1636084130797,"gmtModify":1636084131034,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846230147","repostId":"1128227989","repostType":4,"repost":{"id":"1128227989","kind":"news","pubTimestamp":1636067303,"share":"https://www.laohu8.com/m/news/1128227989?lang=&edition=full","pubTime":"2021-11-05 07:08","market":"us","language":"en","title":"S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1128227989","media":"Reuters","summary":" - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1","content":"<html><body><p>(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p>\n<p>The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.</p>\n<p>Financials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p>\n<p>“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p>\n<p>The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p>\n<p>The S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.</p>\n<p>Among S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p>\n<p>Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p>\n<p>The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p>\n<p>“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p>\n<p>Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p>\n<p>The S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p>\n<p>About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq extend record streaks, with boost from chip, growth shares\n</h2>\n<h4 class=\"meta\">\n\n\n2021-11-05 07:08 GMT+8   <a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\"><strong>Reuters</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and ...</p>\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\">Web Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","IVV":"标普500指数ETF","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF",".IXIC":"NASDAQ Composite","OEF":"标普100指数ETF-iShares","OEX":"标普100"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128227989","content_text":"(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.\nThe Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.\nFinancials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.\n“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\n“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”\nThe Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.\nThe S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.\nAmong S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.\nQualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.\nThe Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.\n“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.\n“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”\nModerna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.\nData showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.\nThe S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.\nAbout 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848627730,"gmtCreate":1635996159712,"gmtModify":1635996688271,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/848627730","repostId":"2180636457","repostType":4,"isVote":1,"tweetType":1,"viewCount":940,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848969478,"gmtCreate":1635954209681,"gmtModify":1635954209951,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848969478","repostId":"2180522657","repostType":4,"isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827631965,"gmtCreate":1634455706578,"gmtModify":1634455706800,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/827631965","repostId":"2175146556","repostType":4,"isVote":1,"tweetType":1,"viewCount":1366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825481360,"gmtCreate":1634254952690,"gmtModify":1634274405803,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825481360","repostId":"1119722017","repostType":4,"isVote":1,"tweetType":1,"viewCount":996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825414328,"gmtCreate":1634254780169,"gmtModify":1634274402797,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825414328","repostId":"2175118595","repostType":4,"isVote":1,"tweetType":1,"viewCount":1059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825415746,"gmtCreate":1634254767393,"gmtModify":1634274408499,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825415746","repostId":"2175118595","repostType":4,"isVote":1,"tweetType":1,"viewCount":751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865704852,"gmtCreate":1633015441849,"gmtModify":1633015442102,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/865704852","repostId":"2171956958","repostType":4,"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861265078,"gmtCreate":1632498942294,"gmtModify":1632715326797,"author":{"id":"3582695539757022","authorId":"3582695539757022","name":"crisscut","avatar":"https://static.tigerbbs.com/f5b06825cc908cd5d8377e102212b090","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582695539757022","authorIdStr":"3582695539757022"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861265078","repostId":"1104085778","repostType":4,"repost":{"id":"1104085778","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632498166,"share":"https://www.laohu8.com/m/news/1104085778?lang=&edition=full","pubTime":"2021-09-24 23:42","market":"us","language":"en","title":"IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.","url":"https://stock-news.laohu8.com/highlight/detail?id=1104085778","media":"Tiger Newspress","summary":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nS","content":"<html><body><p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p>\n<p><img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-height=\"560\" tg-width=\"902\"/></p>\n<p><b>Company & Technology</b></p>\n<p>San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p>\n<p>Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p>\n<p>The company’s primary offerings in its Cue Integrated Care Platform:</p>\n<ul>\n<li><p>Health monitoring system</p></li>\n<li><p>Rader</p></li>\n<li><p>Cartridge</p></li>\n<li><p>Wand</p></li>\n<li><p>Data</p></li>\n<li><p>Delivery apps</p></li>\n<li><p>Enterprise dashboard</p></li>\n<li><p>Ecosystem integrations</p></li>\n</ul>\n<p>Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p>\n<p><b>Customer/User Acquisition</b></p>\n<p>The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p>\n<p>Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p>\n<table>\n<tbody>\n<tr>\n<td><p><b>Sales and Marketing</b></p></td>\n<td><p><b>Expenses vs. Revenue</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Percentage</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>1.0%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>3.1%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>1.3%</p></td>\n</tr>\n</tbody>\n</table>\n<p>The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p>\n<table>\n<tbody>\n<tr>\n<td><p><b>Sales and Marketing</b></p></td>\n<td><p><b>Efficiency Rate</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Multiple</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>100.5</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>22.9</p></td>\n</tr>\n</tbody>\n</table>\n<p><b>Market & Competition</b></p>\n<p>According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p>\n<p>This represents a forecast CAGR of 5.05% from 2021 to 2027.</p>\n<p>The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p>\n<p>Also, below is a chart showing the market share of use of detection kits by end-user type:</p>\n<p><img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-height=\"618\" tg-width=\"1158\"/></p>\n<p>(Source)</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n<li><p>Abbott Laboratories(NYSE:ABT)</p></li>\n<li><p>Becton, Dickinson(NYSE:BDX)</p></li>\n<li><p>bioMerieux(OTCPK:BMXMF)</p></li>\n<li><p>Bio-Rad Laboratories(NYSE:BIO)</p></li>\n<li><p>Danaher(NYSE:DHR)</p></li>\n<li><p>Ellume Limited</p></li>\n<li><p>Everly Health</p></li>\n<li><p>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p></li>\n<li><p>Fluidigm(NASDAQ:FLDM)</p></li>\n<li><p>GenMark Diagnostics(NASDAQ:GNMK)</p></li>\n<li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Cue’s recent financial results can be summarized as follows:</p>\n<ul>\n<li><p>Sharply growing top line revenue</p></li>\n<li><p>Increasing gross profit and variable gross margin</p></li>\n<li><p>A swing to operating profit and net income</p></li>\n<li><p>Variable cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n<colgroup></colgroup>\n<tbody>\n<tr>\n<td><p><b>Total Revenue</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Total Revenue</p></td>\n<td><p>% Variance vs. Prior</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 201,922,000</p></td>\n<td><p>3971.0%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ 22,953,000</p></td>\n<td><p>246.4%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ 6,626,000</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Gross Profit (Loss)</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Gross Profit (Loss)</p></td>\n<td><p>% Variance vs. Prior</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 116,745,000</p></td>\n<td><p>2253.7%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ 8,002,000</p></td>\n<td><p>20.8%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ 6,626,000</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Gross Margin</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Gross Margin</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>57.82%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>34.86%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>100.00%</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Operating Profit (Loss)</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Operating Profit (Loss)</p></td>\n<td><p>Operating Margin</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 79,463,000</p></td>\n<td><p>39.4%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ (45,126,000)</p></td>\n<td><p>-196.6%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ (20,767,000)</p></td>\n<td><p>-313.4%</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Net Income (Loss)</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Net Income (Loss)</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 32,840,000</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ (47,352,000)</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ (20,606,000)</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Cash Flow From Operations</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Cash Flow From Operations</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ (37,812,000)</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ 92,655,000</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ (12,996,000)</p></td>\n</tr>\n</tbody>\n</table>\n<p>As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n<colgroup></colgroup>\n<tbody>\n<tr>\n<td><p><b>Measure [TTM]</b></p></td>\n<td><p><b>Amount</b></p></td>\n</tr>\n<tr>\n<td><p>Market Capitalization at IPO</p></td>\n<td><p>$2,299,981,232</p></td>\n</tr>\n<tr>\n<td><p>Enterprise Value</p></td>\n<td><p>$1,874,455,232</p></td>\n</tr>\n<tr>\n<td><p>Price / Sales</p></td>\n<td><p>10.46</p></td>\n</tr>\n<tr>\n<td><p>EV / Revenue</p></td>\n<td><p>8.52</p></td>\n</tr>\n<tr>\n<td><p>EV / EBITDA</p></td>\n<td><p>35.46</p></td>\n</tr>\n<tr>\n<td><p>Earnings Per Share</p></td>\n<td><p>$0.03</p></td>\n</tr>\n<tr>\n<td><p>Float To Outstanding Shares Ratio</p></td>\n<td><p>8.70%</p></td>\n</tr>\n<tr>\n<td><p>Proposed IPO Midpoint Price per Share</p></td>\n<td><p>$16.00</p></td>\n</tr>\n<tr>\n<td><p>Net Free Cash Flow</p></td>\n<td><p>-$59,920,000</p></td>\n</tr>\n<tr>\n<td><p>Free Cash Flow Yield Per Share</p></td>\n<td><p>-2.61%</p></td>\n</tr>\n<tr>\n<td><p>Revenue Growth Rate</p></td>\n<td><p>3971.01%</p></td>\n</tr>\n</tbody>\n</table>\n<p>As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p>\n<table>\n<colgroup></colgroup>\n<tbody>\n<tr>\n<td><p><b>Metric</b></p></td>\n<td><p><b>Bio-Rad (BIO)</b></p></td>\n<td><p><b>Cue Health (HLTH)</b></p></td>\n<td><p><b>Variance</b></p></td>\n</tr>\n<tr>\n<td><p>Price / Sales</p></td>\n<td><p>8.15</p></td>\n<td><p>10.46</p></td>\n<td><p>28.3%</p></td>\n</tr>\n<tr>\n<td><p>EV / Revenue</p></td>\n<td><p>7.82</p></td>\n<td><p>8.52</p></td>\n<td><p>9.0%</p></td>\n</tr>\n<tr>\n<td><p>EV / EBITDA</p></td>\n<td><p>31.66</p></td>\n<td><p>35.46</p></td>\n<td><p>12.0%</p></td>\n</tr>\n<tr>\n<td><p>Earnings Per Share</p></td>\n<td><p>$134.05</p></td>\n<td><p>$0.03</p></td>\n<td><p>-100.0%</p></td>\n</tr>\n<tr>\n<td><p>Revenue Growth Rate</p></td>\n<td><p>25.6%</p></td>\n<td><p>3971.01%</p></td>\n<td><p>15436.03%</p></td>\n</tr>\n<tr>\n<td><p>(Glossary Of Terms)</p></td>\n</tr>\n</tbody>\n</table>\n<p><b>Commentary</b></p>\n<p>Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p>\n<p>The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p>\n<p>The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p>\n<p>Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p>\n<p>As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p>\n<p>Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-24 23:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p>\n<p><img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-height=\"560\" tg-width=\"902\"/></p>\n<p><b>Company & Technology</b></p>\n<p>San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p>\n<p>Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p>\n<p>The company’s primary offerings in its Cue Integrated Care Platform:</p>\n<ul>\n<li><p>Health monitoring system</p></li>\n<li><p>Rader</p></li>\n<li><p>Cartridge</p></li>\n<li><p>Wand</p></li>\n<li><p>Data</p></li>\n<li><p>Delivery apps</p></li>\n<li><p>Enterprise dashboard</p></li>\n<li><p>Ecosystem integrations</p></li>\n</ul>\n<p>Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p>\n<p><b>Customer/User Acquisition</b></p>\n<p>The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p>\n<p>Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p>\n<table>\n<tbody>\n<tr>\n<td><p><b>Sales and Marketing</b></p></td>\n<td><p><b>Expenses vs. Revenue</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Percentage</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>1.0%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>3.1%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>1.3%</p></td>\n</tr>\n</tbody>\n</table>\n<p>The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p>\n<table>\n<tbody>\n<tr>\n<td><p><b>Sales and Marketing</b></p></td>\n<td><p><b>Efficiency Rate</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Multiple</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>100.5</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>22.9</p></td>\n</tr>\n</tbody>\n</table>\n<p><b>Market & Competition</b></p>\n<p>According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p>\n<p>This represents a forecast CAGR of 5.05% from 2021 to 2027.</p>\n<p>The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p>\n<p>Also, below is a chart showing the market share of use of detection kits by end-user type:</p>\n<p><img referrerpolicy=\"no-referrer\" src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-height=\"618\" tg-width=\"1158\"/></p>\n<p>(Source)</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n<li><p>Abbott Laboratories(NYSE:ABT)</p></li>\n<li><p>Becton, Dickinson(NYSE:BDX)</p></li>\n<li><p>bioMerieux(OTCPK:BMXMF)</p></li>\n<li><p>Bio-Rad Laboratories(NYSE:BIO)</p></li>\n<li><p>Danaher(NYSE:DHR)</p></li>\n<li><p>Ellume Limited</p></li>\n<li><p>Everly Health</p></li>\n<li><p>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p></li>\n<li><p>Fluidigm(NASDAQ:FLDM)</p></li>\n<li><p>GenMark Diagnostics(NASDAQ:GNMK)</p></li>\n<li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Cue’s recent financial results can be summarized as follows:</p>\n<ul>\n<li><p>Sharply growing top line revenue</p></li>\n<li><p>Increasing gross profit and variable gross margin</p></li>\n<li><p>A swing to operating profit and net income</p></li>\n<li><p>Variable cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n<colgroup></colgroup>\n<tbody>\n<tr>\n<td><p><b>Total Revenue</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Total Revenue</p></td>\n<td><p>% Variance vs. Prior</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 201,922,000</p></td>\n<td><p>3971.0%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ 22,953,000</p></td>\n<td><p>246.4%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ 6,626,000</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Gross Profit (Loss)</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Gross Profit (Loss)</p></td>\n<td><p>% Variance vs. Prior</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 116,745,000</p></td>\n<td><p>2253.7%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ 8,002,000</p></td>\n<td><p>20.8%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ 6,626,000</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Gross Margin</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Gross Margin</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>57.82%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>34.86%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>100.00%</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Operating Profit (Loss)</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Operating Profit (Loss)</p></td>\n<td><p>Operating Margin</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 79,463,000</p></td>\n<td><p>39.4%</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ (45,126,000)</p></td>\n<td><p>-196.6%</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ (20,767,000)</p></td>\n<td><p>-313.4%</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Net Income (Loss)</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Net Income (Loss)</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ 32,840,000</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ (47,352,000)</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ (20,606,000)</p></td>\n</tr>\n<tr></tr>\n<tr>\n<td><p><b>Cash Flow From Operations</b></p></td>\n</tr>\n<tr>\n<td><p>Period</p></td>\n<td><p>Cash Flow From Operations</p></td>\n</tr>\n<tr>\n<td><p>Six Mos. Ended June 30, 2021</p></td>\n<td><p>$ (37,812,000)</p></td>\n</tr>\n<tr>\n<td><p>2020</p></td>\n<td><p>$ 92,655,000</p></td>\n</tr>\n<tr>\n<td><p>2019</p></td>\n<td><p>$ (12,996,000)</p></td>\n</tr>\n</tbody>\n</table>\n<p>As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n<colgroup></colgroup>\n<tbody>\n<tr>\n<td><p><b>Measure [TTM]</b></p></td>\n<td><p><b>Amount</b></p></td>\n</tr>\n<tr>\n<td><p>Market Capitalization at IPO</p></td>\n<td><p>$2,299,981,232</p></td>\n</tr>\n<tr>\n<td><p>Enterprise Value</p></td>\n<td><p>$1,874,455,232</p></td>\n</tr>\n<tr>\n<td><p>Price / Sales</p></td>\n<td><p>10.46</p></td>\n</tr>\n<tr>\n<td><p>EV / Revenue</p></td>\n<td><p>8.52</p></td>\n</tr>\n<tr>\n<td><p>EV / EBITDA</p></td>\n<td><p>35.46</p></td>\n</tr>\n<tr>\n<td><p>Earnings Per Share</p></td>\n<td><p>$0.03</p></td>\n</tr>\n<tr>\n<td><p>Float To Outstanding Shares Ratio</p></td>\n<td><p>8.70%</p></td>\n</tr>\n<tr>\n<td><p>Proposed IPO Midpoint Price per Share</p></td>\n<td><p>$16.00</p></td>\n</tr>\n<tr>\n<td><p>Net Free Cash Flow</p></td>\n<td><p>-$59,920,000</p></td>\n</tr>\n<tr>\n<td><p>Free Cash Flow Yield Per Share</p></td>\n<td><p>-2.61%</p></td>\n</tr>\n<tr>\n<td><p>Revenue Growth Rate</p></td>\n<td><p>3971.01%</p></td>\n</tr>\n</tbody>\n</table>\n<p>As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p>\n<table>\n<colgroup></colgroup>\n<tbody>\n<tr>\n<td><p><b>Metric</b></p></td>\n<td><p><b>Bio-Rad (BIO)</b></p></td>\n<td><p><b>Cue Health (HLTH)</b></p></td>\n<td><p><b>Variance</b></p></td>\n</tr>\n<tr>\n<td><p>Price / Sales</p></td>\n<td><p>8.15</p></td>\n<td><p>10.46</p></td>\n<td><p>28.3%</p></td>\n</tr>\n<tr>\n<td><p>EV / Revenue</p></td>\n<td><p>7.82</p></td>\n<td><p>8.52</p></td>\n<td><p>9.0%</p></td>\n</tr>\n<tr>\n<td><p>EV / EBITDA</p></td>\n<td><p>31.66</p></td>\n<td><p>35.46</p></td>\n<td><p>12.0%</p></td>\n</tr>\n<tr>\n<td><p>Earnings Per Share</p></td>\n<td><p>$134.05</p></td>\n<td><p>$0.03</p></td>\n<td><p>-100.0%</p></td>\n</tr>\n<tr>\n<td><p>Revenue Growth Rate</p></td>\n<td><p>25.6%</p></td>\n<td><p>3971.01%</p></td>\n<td><p>15436.03%</p></td>\n</tr>\n<tr>\n<td><p>(Glossary Of Terms)</p></td>\n</tr>\n</tbody>\n</table>\n<p><b>Commentary</b></p>\n<p>Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p>\n<p>The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p>\n<p>The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p>\n<p>Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p>\n<p>As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p>\n<p>Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLTH":"Cue Health Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104085778","content_text":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n\nHealth monitoring system\nRader\nCartridge\nWand\nData\nDelivery apps\nEnterprise dashboard\nEcosystem integrations\n\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n\n\n\nSales and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n1.0%\n\n\n2020\n3.1%\n\n\n2019\n1.3%\n\n\n\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n\n\n\nSales and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n100.5\n\n\n2020\n22.9\n\n\n\nMarket & Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n\n(Source)\nMajor competitive or other industry participants include:\n\nAbbott Laboratories(NYSE:ABT)\nBecton, Dickinson(NYSE:BDX)\nbioMerieux(OTCPK:BMXMF)\nBio-Rad Laboratories(NYSE:BIO)\nDanaher(NYSE:DHR)\nEllume Limited\nEverly Health\nRoche(OTCQX:RHHBY)(OTCQX:RHHBF)\nFluidigm(NASDAQ:FLDM)\nGenMark Diagnostics(NASDAQ:GNMK)\nOthers\n\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n\nSharply growing top line revenue\nIncreasing gross profit and variable gross margin\nA swing to operating profit and net income\nVariable cash flow from operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 201,922,000\n3971.0%\n\n\n2020\n$ 22,953,000\n246.4%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 116,745,000\n2253.7%\n\n\n2020\n$ 8,002,000\n20.8%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n57.82%\n\n\n2020\n34.86%\n\n\n2019\n100.00%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 79,463,000\n39.4%\n\n\n2020\n$ (45,126,000)\n-196.6%\n\n\n2019\n$ (20,767,000)\n-313.4%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 32,840,000\n\n\n2020\n$ (47,352,000)\n\n\n2019\n$ (20,606,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ (37,812,000)\n\n\n2020\n$ 92,655,000\n\n\n2019\n$ (12,996,000)\n\n\n\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$2,299,981,232\n\n\nEnterprise Value\n$1,874,455,232\n\n\nPrice / Sales\n10.46\n\n\nEV / Revenue\n8.52\n\n\nEV / EBITDA\n35.46\n\n\nEarnings Per Share\n$0.03\n\n\nFloat To Outstanding Shares Ratio\n8.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$59,920,000\n\n\nFree Cash Flow Yield Per Share\n-2.61%\n\n\nRevenue Growth Rate\n3971.01%\n\n\n\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nBio-Rad (BIO)\nCue Health (HLTH)\nVariance\n\n\nPrice / Sales\n8.15\n10.46\n28.3%\n\n\nEV / Revenue\n7.82\n8.52\n9.0%\n\n\nEV / EBITDA\n31.66\n35.46\n12.0%\n\n\nEarnings Per Share\n$134.05\n$0.03\n-100.0%\n\n\nRevenue Growth Rate\n25.6%\n3971.01%\n15436.03%\n\n\n(Glossary Of Terms)\n\n\n\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.","news_type":1},"isVote":1,"tweetType":1,"viewCount":963,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}